Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Acute Gouty Arthritis Clinical Trial

Official title:
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients

Status Completed

Clinical Trial Summary

This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01431638
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	August 25, 2011
Completion date	May 9, 2013

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01593527` - Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease	Phase 3
Recruiting	`NCT02545777` - The Clinical Study on Treating Acute Gouty Arthritis Using Both Internal and External Therapy of Tonifying Spleen and Descending Turbid	Phase 2
Completed	`NCT01356602` - Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients	Phase 3
Completed	`NCT00170781` - Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout	Phase 4
Not yet recruiting	`NCT06273813` - Treatment of Topical Ketorolac Gel in Acute Gouty Flare	Phase 1
Completed	`NCT03002974` - A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis	Phase 2